skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia

Original Research

(2635) Views  (636) Full article downloads

Authors: Catalin Mindrescu, Rakesh P Gupta, Eileen V Hermance, Mary C DeVoe, Vikas R Soma, et al

Published Date December 2008 Volume 2008:4(6) Pages 1439 - 1447
DOI: http://dx.doi.org/10.2147/VHRM.S4001

Catalin Mindrescu1,2,3, Rakesh P Gupta1,3, Eileen V Hermance1, Mary C DeVoe1, Vikas R Soma1, John T Coppola1,2, Cezar S Staniloae1,2

1Comprehensive Cardiovascular Center, Saint Vincent’s Hospital Manhattan, New York, NY, USA; 2New York Medical College, Valhalla, NY, USA; 3Rakesh P Gupta and Catalin Mindrescu contributed equally to this article.

Background: The present study was undertaken to investigate the effect of statins plus omega-3 polyunsaturated fatty acids (PUFAs) on endothelial function and lipid profile in South Asians with dyslipidemia and endothelial dysfunction, a population at high risk for premature coronary artery disease.

Methods: Thirty subjects were randomized to rosuvastatin 10 mg and omega-3-PUFAs 4 g or rosuvastatin 10 mg. After 4 weeks, omega-3-PUFAs were removed from the first group and added to subjects in the second group. All subjects underwent baseline, 4-, and 8-week assessment of endothelial function and lipid profile.

Results: Compared to baseline, omega-3-PUFAs plus rosuvastatin improved endothelial-dependent vasodilation (EDV: −1.42% to 11.36%, p = 0.001), and endothelial-independent vasodilation (EIV: 3.4% to 17.37%, p = 0.002). These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003). In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline. However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (−0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001). Addition of omega-3-PUFAs further improved the lipid profile (triglycerides 139 to 91 mg/dl, p = 0.006, low-density lipoprotein cholesterol 116 to 88 mg/dl, p = 0.014).

Conclusions: Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial function in South Asian subjects with dyslipidemia and endothelial dysfunction.

Keywords: omega-3 fatty acids, endothelial function, South Asians, dyslipidemia, rosuvastatin






 

Other articles by Dr Catalin Mindrescu



Readers of this article also read:

Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy
Role of stress fibers and focal adhesions as a mediator for mechano-signal transduction in endothelial cells in situ
Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study
Study of the intima-media thickening in carotid arteries of healthy elderly with high blood pressure and elderly with high blood pressure and dyslipidemia
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Venous and arterial thrombosis: Two aspects of the same disease?
Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy
Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University